Table 2 Incidence of adverse events
From: Use, tolerability and compliance of spironolactone in the treatment of heart failure
Spironolactone users | Spironolactone non-users | |
|---|---|---|
Hyperkalemia | 408/12,344 (3.3%) | 955/69,674 (1.4%)* |
Breast complications in men | 158/6,368 (2.5%) | 380/32,764 (1.2%)* |
Breast hypertrophy in men (gynecomastia) | 117/6,368 (1.8%) | 233/32,764 (0.7%)* |